Symphony Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Symphony Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-4,500	Closed	-$636K	–	414
2016 Q2	$636K	Buy	+4,500	New	+$663K	0.07%	217
2015 Q4	–	Sell	-1,869	Closed	-$248K	–	442
2015 Q3	$248K	Buy	+1,869	New	+$322K	0.03%	400
2015 Q2	–	Sell	-1,583	Closed	-$274K	–	455
2015 Q1	$274K	Buy	1,583 +229	+17%	+$39.3K	0.03%	432
2014 Q4	$221K	Sell	1,354 -23,967	-95%	-$3.98M	0.03%	374
2014 Q3	$4.07M	Buy	25,321 +19,236	+316%	+$2.96M	0.42%	47
2014 Q2	$895K	Buy	6,085 +797	+15%	+$111K	0.09%	235
2014 Q1	$733K	Sell	5,288 -4,817	-48%	-$725K	0.07%	244
2013 Q4	$1.28M	Sell	10,105 -8,724	-46%	-$903K	0.09%	182
2013 Q3	$1.73M	Buy	18,829 +3,283	+21%	+$265K	0.18%	132
2013 Q2	$1.07M	Buy	+15,546	New	+$950K	0.1%	180

Other funds holding JAZZ

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Symphony Asset Management's JAZZ Position: Q3 2016 in Review

Symphony Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2016, closing a stake of 4,500 shares — an estimated $636K sold.

Symphony Asset Management first reported a position in JAZZ in Q2 2013 and held it in 10 quarters. The position peaked at $4.07M in Q3 2014. 325 funds tracked by Wall St. Rank hold JAZZ as of Q3 2016.

Symphony Asset Management reported no remaining Jazz Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
Symphony Asset Management sold 4,500 Jazz Pharmaceuticals shares in Q3 2016, an estimated $636K.
Symphony Asset Management first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 10 quarters.
Symphony Asset Management's Jazz Pharmaceuticals position peaked at $4.07M in Q3 2014.
325 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2016.

Based on Symphony Asset Management's 13F filing for Q3 2016, filed 14 Nov 2016.